xtremepicks.com: www.Xtremepicks.Com: "Xtreme Picks" Alerts November 9, 2009 : CYTR, RXII, ATRN, TROW, VIMC and CFFN

CytRx Corporation (NASDAQ: CYTR | Quote | Chart | News | PowerRating) trading at $0.956 on a volume of 368,709 shares

In a press release out on November 9, CytRx Reports 2009 Third Quarter Financial Results

LOS ANGELES, Nov 09, 2009 -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 36% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visitwww.cytrx.com.

RXi Pharmaceuticals Corporation (Nasdaq: RXII | Quote | Chart | News | PowerRating) trading at $9.17 on a volume of 9,397 shares

In a press release out on November 9, RXi Pharmaceuticals Appoints Noah D. Beerman as CEO

Business Veteran Brings to RXi a Successful Track Record of Building a Pipeline of Biopharmaceutical Products

WORCESTER, Mass., Nov 06, 2009 -- RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah D. Beerman has joined the company as its new President and Chief Executive Officer. The appointment of Mr. Beerman as CEO is part of a planned succession in leadership as the company looks to advance from the research stage to product development and execution of therapeutic collaborations and partnerships. He succeeds RXi's co-founder, Tod Woolf, Ph.D., who will continue as a member of RXi's Scientific Advisory Board (SAB).

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and potential delivery methods. RXi uses its own version of RNAi compounds -- rxRNA(TM) -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and may define the next generation of RNAi technology. rxRNA(TM) compounds are designed specifically for therapeutic use and contain many of the properties needed to move RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. www.rxipharma.com

Atrinsic (NASDAQ:ATRN) trading at $1.06 on a volume of 3,650 shares

In a press release out on November 9, Atrinsic to Announce 2009 Third Quarter Results on November 11, 2009

Conference Call to be held at 8:30 a.m. ET on November 11

NEW YORK, Nov 09, 2009 -- Atrinsic (NASDAQ:ATRN), one of the fastest growing digital advertising and entertainment networks in the United States, announced today that management will report its 2009 third quarter financial results before market opens on Wednesday, November 11, 2009. Management will then host a conference call at 8:30 a.m. Eastern Time on Wednesday, November 11, 2009, to discuss the results with the investment community.

About Atrinsic

Atrinsic, Inc. is one of the leading cross-platform digital content and online marketing services networks in the United States. Atrinsic brings together the power of the Internet and the latest in mobile technology to drive consumer audiences to its network of owned, branded content sites as well as third party media that feature web, mobile and social networking applications. The company delivers high quality leads for both its own proprietary subscription clubs and its advertisers and monetizes these audiences through performance-based advertising, direct billed subscription clubs and agency services.

T. Rowe Price Group (Nasdaq: TROW | Quote | Chart | News | PowerRating) trading at $50.40 on a volume of 1.15M shares

In a press release out on November 9, T. Rowe Price to Acquire Stake in UTI Asset Management Company

--Cooperative relationship with Indian investment management firm offers growth opportunities in the rapidly developing Indian market

BALTIMORE, Nov 09, 2009 -- T. Rowe Price Group (Nasdaq: TROW | Quote | Chart | News | PowerRating) today announced that it has entered into definitive agreements to acquire a 26% stake in UTI Asset Management Company Limited and UTI Trustee Company Pvt. Ltd. for INR 6.5 billion (approximately $138 million based on current exchange rates). The transaction is subject to receipt of requisite regulatory approvals and is expected to close in the fourth quarter of 2009.

Founded in 1937, Baltimore-based T. Rowe Price Group, Inc. (www.troweprice.com) is a global investment management organization with $366.2 billion in assets as of September 30, 2009. The organization provides a broad array of mutual funds, sub-advisory services, and separate account management for financial intermediaries, individual and institutional investors, and retirement plans. The company also offers sophisticated investment planning and guidance tools. T. Rowe Price's disciplined, risk-aware investment approach focuses on diversification, style consistency, and fundamental research.

Vimicro International Corporation (Nasdaq: VIMC | Quote | Chart | News | PowerRating) trading at $3.83 on a volume of 45,642 shares

In a press release out on November 9, Vimicro Announces Strategic Development Agreement with China Satellite Mobile Broadcasting Corporation for CMMB Mobile TV Standard

BEIJING, Nov 09, 2009 -- Vimicro International Corporation (Nasdaq: VIMC | Quote | Chart | News | PowerRating) ("Vimicro"), a leading multimedia semiconductor and solution provider, today announced a strategic development partnership with China Satellite Mobile Broadcasting Corporation ("CSMBC") to advance the development of mobile TV under the China Mobile Multimedia Broadcasting ("CMMB") standard. CSMBC is a wholly-owned subsidiary of The State Administration of Radio Film and Television ("SARFT") and the national operator of CMMB.

About Vimicro International Corporation

Vimicro International Corporation is a leading multimedia semiconductor and solution provider that designs, develops and markets mixed-signal semiconductor products and system-level solutions that enable multimedia capabilities in a variety of products for the consumer electronics and communications markets. Vimicro is also expanding business into the surveillance market with system-level solutions and semiconductor products. Vimicro's ADSs, each of which represents four ordinary shares, are currently trading on the NASDAQ Global Market under the ticker symbol "VIMC."

Capitol Federal Financial (Nasdaq: CFFN | Quote | Chart | News | PowerRating) trading at $30.19 on a volume of 38,074 shares

In a press release out on November 9, Capitol Federal Financial Reports Fiscal Year 2009 Results

TOPEKA, Kan., Nov 09, 2009 -- Capitol Federal Financial (Nasdaq: CFFN | Quote | Chart | News | PowerRating) (the "Company") announced results today for the fiscal year ended September 30, 2009. Detailed results will be available in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2009, which will be filed with the Securities and Exchange Commission on or about November 30, 2009 and posted on our website, http://ir.capfed.com/sec.cfm.

Capitol Federal Financial is the holding company for Capitol Federal Savings Bank. Capitol Federal Savings Bank has 42 branch locations in Kansas, nine of which are in-store branches. Capitol Federal Savings Bank employs 676 full time equivalent employees in the operation of its business and is one of the largest residential lenders in the State of Kansas.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com
e-mail: Info@xtremepicks.com
WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Vimicro International Inc (VIMC) VIMC. Vimicro International Inc (VIMC) has Short Term PowerRatings at TradingMarkets. Details on Vimicro International Inc (VIMC) Short Term PowerRatings is available at This Link.

For full details on Capitol Federal Fncl (CFFN) CFFN. Capitol Federal Fncl (CFFN) has Short Term PowerRatings at TradingMarkets. Details on Capitol Federal Fncl (CFFN) Short Term PowerRatings is available at This Link.

For full details on Cytrx Corporation (CYTR) CYTR. Cytrx Corporation (CYTR) has Short Term PowerRatings at TradingMarkets. Details on Cytrx Corporation (CYTR) Short Term PowerRatings is available at This Link.

For full details on T. Rowe Price Group, Inc. (TROW) TROW. T. Rowe Price Group, Inc. (TROW) has Short Term PowerRatings at TradingMarkets. Details on T. Rowe Price Group, Inc. (TROW) Short Term PowerRatings is available at This Link.

For full details on RXi Pharmaceuticals Corporation (RXII) RXII. RXi Pharmaceuticals Corporation (RXII) has Short Term PowerRatings at TradingMarkets. Details on RXi Pharmaceuticals Corporation (RXII) Short Term PowerRatings is available at This Link.

For full details on Atrinsic Inc (ATRN) ATRN. Atrinsic Inc (ATRN) has Short Term PowerRatings at TradingMarkets. Details on Atrinsic Inc (ATRN) Short Term PowerRatings is available at This Link.